CS
MLYS icon

Candriam SCA’s Mineralys Therapeutics MLYS Stock Holding History

Candriam SCA’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1M Buy
857,037
+55,133
+7% +$1.51M 0.1% 187
2026
Q1 		$21.7M Buy
801,904
+123,517
+18% +$3.62M 0.11% 181
2025
Q4 		$24.6M Buy
678,387
+110,606
+19% +$4.44M 0.12% 167
2025
Q3 		$21.5M Sell
567,781
-256,406
-31% -$5.55M 0.11% 175
2025
Q2 		$11.2M Sell
824,187
-58,646
-7% -$850K 0.06% 233
2025
Q1 		$14M Buy
882,833
+577,561
+189% +$6.64M 0.09% 202
2024
Q4 		$3.76M Buy
+305,272
New +$3.99M 0.02% 397

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Candriam SCA's MLYS Position: Q2 2026 in Review

Candriam SCA increased its Mineralys Therapeutics (MLYS) stake by 6.9% in Q2 2026, buying an estimated $1.51M and bringing the position to 857,037 shares worth $23.1M. The position accounts for 0.1% of the portfolio, ranked #187.

Candriam SCA first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. The position peaked at $24.6M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Candriam SCA held 857,037 shares of Mineralys Therapeutics worth $23.1M as of Q2 2026.
  • Candriam SCA bought 55,133 Mineralys Therapeutics shares in Q2 2026, an estimated $1.51M.
  • Mineralys Therapeutics made up 0.1% of Candriam SCA's portfolio in Q2 2026, its #187 holding.
  • Candriam SCA first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Candriam SCA's Mineralys Therapeutics position peaked at $24.6M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.